Natera, Inc.
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Patients Revenue by Quarter
Patients Revenue — Self-Pay & Out-of-Pocket Co-Pays ($M) ($M)
Natera Patients Revenue: $9.92M in Q2 2026, up 33.3% from a year earlier.
Latest, Q2 2026
9.92
Period ended Jun 30, 2026
Change on a year earlier
+33.3%
7.44 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (2026-08-07) ↗
Direct patient self-pay revenue and patient deductibles/co-insurance collections.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Patients Revenue — Self-Pay & Out-of-Pocket Co-Pays ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 9.92 | +33.3% | Form 10-Q (2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 9.74 | +16.6% | Form 10-Q (2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 8.43 | +11.7% | Form 10-K (2026-02-27) ↗ |
| Q3 2025 | Sep 30, 2025 | 7.58 | +9.4% | Form 10-Q (2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 7.44 | +6.7% | Form 10-Q (2026-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 8.35 | +29.7% | Form 10-Q (2026-05-08) ↗ |
| Q4 2024 | Dec 31, 2024 | 7.55 | +12.4% | Form 10-K (2026-02-27) ↗ |
| Q3 2024 | Sep 30, 2024 | 6.93 | +2.1% | Form 10-Q (2025-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 6.97 | -6.2% | Form 10-Q (2025-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 6.44 | -24.9% | Form 10-Q (2025-05-09) ↗ |
| Q4 2023 | Dec 31, 2023 | 6.72 | -24.6% | Form 10-K (2026-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 6.79 | -22.5% | Form 10-Q (2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 7.43 | -9.8% | Form 10-Q (2024-08-09) ↗ |
| Q1 2023 | Mar 31, 2023 | 8.57 | -0.9% | Form 10-Q (2024-05-10) ↗ |
| Q4 2022 | Dec 31, 2022 | 8.91 | -3.6% | Form 10-K (2025-02-28) ↗ |
| Q3 2022 | Sep 30, 2022 | 8.76 | +6.2% | Form 10-Q (2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 8.24 | +2.6% | Form 10-Q (2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 8.65 | +17.2% | Form 10-Q (2023-05-10) ↗ |
| Q4 2021 | Dec 31, 2021 | 9.24 | -27.2% | Form 10-K (2024-02-29) ↗ |
| Q3 2021 | Sep 30, 2021 | 8.25 | +28.1% | Form 10-Q (2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 8.03 | +38.4% | Form 10-Q (2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 7.38 | -3.7% | Form 10-Q (2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 12.7 | +73.6% | Form 10-K (2023-03-01) ↗ |
| Q3 2020 | Sep 30, 2020 | 6.44 | -29.8% | Form 10-Q (2021-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 5.80 | -31.4% | Form 10-Q (2021-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 7.66 | +16.1% | Form 10-Q (2021-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 7.31 | +16.2% | Form 10-K (2022-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 9.17 | +67.0% | Form 10-Q (2020-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 8.45 | +82.9% | Form 10-Q (2020-08-07) ↗ |
| Q1 2019 | Mar 31, 2019 | 6.60 | +99.4% | Form 10-Q (2020-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 6.29 | +109.0% | Form 10-K (2021-02-26) ↗ |
| Q3 2018 | Sep 30, 2018 | 5.49 | +148.4% | Form 10-Q (2019-11-08) ↗ |
| Q2 2018 | Jun 30, 2018 | 4.62 | +122.1% | Form 10-Q (2019-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 3.31 | +35.1% | Form 10-Q (2019-05-10) ↗ |
| Q4 2017 | Dec 31, 2017 | 3.01 | – | Form 10-K (2020-03-02) ↗ |
| Q3 2017 | Sep 30, 2017 | 2.21 | – | Form 10-Q (2018-11-09) ↗ |
| Q2 2017 | Jun 30, 2017 | 2.08 | – | Form 10-Q (2018-08-09) ↗ |
| Q1 2017 | Mar 31, 2017 | 2.45 | – | Form 10-Q (2018-03-31) ↗ |
Cite this data
StockData. (2026). Natera Patients Revenue ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/rev-payer-patients
See every metric in the Natera KPI table. Data updated Nov 2, 2026.